Lung Cancer

A study conducted by SEER and Medicare revealed that nearly half of older patients diagnosed with metastatic non-small cell lung cancer never received systemic therapy.

Gotistobart reduced death risk by 54% and doubled 12-month survival vs chemo in pretreated advanced squamous NSCLC, per PRESERVE-003 results.

Nuvalent submitted an NDA for neladalkib in TKI-pretreated ALK+ NSCLC, supported by ALKOVE-1 data showing systemic and intracranial activity with tolerability.

Zongertinib elicited responses in patients with advanced HER2-mutant NSCLC, showing intracranial efficacy in those with active brain metastases, per phase 1b Beamion LUNG-1 data.

Adagrasib shows efficacy in elderly patients with KRAS G12C-mutant NSCLC and an ECOG PS of 0-1, while those with a PS of 2 see limited survival benefit but QOL improvements.

Calderasib, a potent KRAS G12C inhibitor, demonstrated improved outcomes in patients with metastatic NSCLC, especially when combined with pembrolizumab.

Explore phase 1 data for setidegrasib, a novel KRAS G12D-targeted protein degrader showing antitumor activity and manageable infusion-related reactions in patients with advanced NSCLC.

The FDA issued a complete response letter to retifanlimab due to inspection findings at a third-party facility.

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s National Priority Voucher pilot program.

Of 9 evaluable patients with progressive non–small cell lung cancer (NSCLC) and progressive SCLC, 6 achieved disease control with Olvi-Vec.

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment.

New clinical data highlight the impact of infusion timing on NSCLC survival, alongside updated ASCO guidelines and FDA RMAT status for inhaled KB707.

Risvutatug rezetecan, an antibody-drug conjugate was granted FDA orphan drug designation for use in patients with small cell lung cancer.

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj across all amivantamab indications.

Catch up on recent regulatory decisions by the FDA in oncology, including actions in lung, hematologic, genitourinary, and gastrointestinal cancers.

Jillian Thompson, MSN, ANP-BC, AOCNP, discusses how COCOON data improve toxicity management for amivantamab/lazertinib in frontline EGFR-positive NSCLC.

The FDA has converted its accelerated approval to a standard one for tarlatamab in extensive-stage small cell lung cancer.

The FDA has approved sevabertinib for the treatment of patients with HER2-positive nonsquamous non-small cell lung cancer.

Adding platinum-based chemotherapy to osimertinib improved overall survival vs osimertinib alone in EGFR-mutated NSCLC, even in high-risk subgroups.

Sevabertinib demonstrated robust, durable responses and manageable safety in both treatment-naive and pretreated patients with HER2-mutant advanced NSCLC.

Ivonescimab plus chemotherapy improved progression-free survival and response rates with manageable safety vs tislelizumab in advanced squamous NSCLC.

Ponsegromab increased body weight in patients with cancer-associated cachexia, yielding greater improvement in those who received ponsegromab previously.

Chemo-induced myelosuppression can affect patients’ ability to do daily tasks, and management varies by patient, treatment regimens, locations, and more.

CRS and ICANS were observed in 48% and 16%, respectively, of patients with ES-SCLC who received tarlatamab, according to real-world data.

The FDA has approved lurbinectedin plus atezolizumab for the treatment of extensive-stage small cell lung cancer following induction therapy with atezolizumab.